Drugs / CMV CTLs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04056533 | Mar 2022 → Mar 2026 overdue | cytomegalovirus infection | Marqués de Valdecilla Research Institute (IDIVAL) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV CTLs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04056533 ↗ |
| Known as | CMV-CTL | “The donor derived cytomegalovirus specific T lymphocytes (CMV-CTL) will be transfused to the patients.” NCT04056533 ↗ |
| Modality | Cell therapy | “strategies based on immunotherapy adoptive cells (IAC) with anti-CMV Cytolitic T Lymphocytes (CMV-CTLs)” NCT04056533 ↗ |
| Route | Intravenous | “The donor derived CMV-CTL cells will be transfused into the patients' intravenous line.” NCT04056533 ↗ |